Incyte Lags Peers as Analysts Split After Q3 Beat
Incyte Corporation trailed its closest biotech peers last week, gaining 0.8% to $117.59 while the peer group median rose 2.4%, a gap that reflects a stock still digesting its Q3 print and carrying a more divided…